...In the first full trading day after the May 19 announcement that AstraZeneca declined Pfizer s takeover offer, the CDS-implied rating for Pfizer rose by one notch from Aa2 to Aa1, while market signals were steady for the bond-implied and EDFTM- implied ratings. Despite a dip to a low point of Aa3 on April 29, Pfizer s CDS-implied rating returned to Aa1 on May 20, matching its April 20 level. The bond-implied rating ticked down one notch from Aa3 to A1 on May 19. It had moved from A1 to Aa3 for two brief periods over the last 30 days (April 23 to April 28 and May 1 to May 19) before settling at A1 again, and remaining unaltered on May 20. The EDFTM- implied rating was unwavering at Aaa for the last 30 days; indeed it has been Aaa since July 17, 2012....